Cystic Fibrosis Associated Liver Disease and Bronchiectasis in Puberty. Case Report and Literature Review

1Lamireau T, Monnereau S, Martin A, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004; 41:920-5.Search in Google Scholar

2Williams SG, Hayller KM, Hodson ME, Westaby D..Prognosis in cystic fibrosis. N Engl J Med. 1992; 327:1244 5.15.Search in Google Scholar

3Rowe S.M., Miller S., Sorscher E.J. Mechanisms of disease, Cystic fibrosis. N. Engl. J. Med., 2005; 352:1992-2001.Search in Google Scholar

4Guido M, Alves VAF, Balabaud C, Bathal PS, Bioulac-Sage P, Colombari R, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology. 2019; 74:219–226.Search in Google Scholar

5Padoan R, Cirilli N, Falchetti D, Cesana BM. Risk factors for adverse outcome in infancy in meconium ileus cystic fibrosis infants: a multicenter Italian study. J Cystic Fibrosis 2019; 18:863–868. Search in Google Scholar

6Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol. 2004; 57:402–406.Search in Google Scholar

7In ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53:726-36. AST to Platelet Ratio Index (APRI).Search in Google Scholar

8Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013; 158:807-20.Search in Google Scholar

9Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis and Liver Disease. 2022 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32310546.Search in Google Scholar

10Jeremy D., Debray D., Beaufrere A., Hillaire S., et al. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol. 2022; 76(2):420-434.Search in Google Scholar

11Lindblad A., Glaumann H., Strandvik B. A Two-Year Prospective Study of the Effect of Ursodeoxycholic Acid on Urinary Bile Acid Excretion and Liver Morphology in Cystic Fibrosis–Associated Liver Disease. Hepatology. 1998; 27(1):166-74.Search in Google Scholar

12Nascimento F., Nelson S., Ferreira T., Marques C.D.F., Silva L., Souza E.L. Hepatobiliary disease in children and adolescents with cystic fibrosis. J Pediatr. 2018; 94(5):504---510.Search in Google Scholar

13Flass T., Narkewickz M.R. Cirrhosis and other liver disease in cystic fibrosis. Department of Pediatrics University of Colorado School of Medicine and The Pediatric Liver Center, Children’s Hospital Colorado, Aurora, CO, USA, 2012.Search in Google Scholar

14Colombo C., Crosignani A., Assaisso M. Battezzati M., Podda M., Giunta A., Zimmer-Nechemias L., Setchell K.D., Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study, Hepatology, 1992; 15; 677-684.Search in Google Scholar

15Gobato AO, Vasques ACJ, Ribeiro AF, Yamada RM, Hessel G. Prevalence of hepatic steatosis among children and adolescents with cystic fibrosis and its association with nutritional status, Rev Paul Pediatry 2019; 37:435–441. Search in Google Scholar